Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds ESS Inc. Issues Statement On Grizzly Research’s Report

News

ESS Inc. Issues Statement On Grizzly Research’s Report

https://essinc.com/ess-inc-statement-on-grizzly-research-report/

byBenzinga Newsdesk

December 7, 2022

1 minute read

https://essinc.com/ess-inc-statement-on-grizzly-research-report/Â

General
News

Hasbro, New York Times Bring ‘Wordle’ To Life Via New Board Game

By Shivani Kumaresan

July 14, 3:12 PM

Hasbro Inc (NASDAQ:HAS) and New York Times Co (NYSE:NYT) are working together to bring Wordle to life in a new board game. Inspired…

HAS

Starbox Bags $2.8M Contract In Malaysia For Licensing Its Software

By Akanksha Bakshi

March 24, 8:56 AM

Starbox Group Holdings Ltd’s (NASDAQ:STBX) Malaysian subsidiary, Starbox Rebates Sdn. Bhd., has entered into a Software Licensing Agreement with Brandavision Sdn…

STBX

Goldman Sachs Maintains Neutral on Equity Residential, Lowers Price Target to $74

By Benzinga Newsdesk

October 18, 9:20 AM

Goldman Sachs analyst Chandni Luthra maintains Equity Residential (NYSE:EQR) with a Neutral and lowers the price target from $86 to $74.

EQR

Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus

By Benzinga Newsdesk

April 4, 4:01 PM

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy

CRBU

ESS Inc. Issues Statement On Grizzly Research’s Report

Related Posts

Hasbro, New York Times Bring ‘Wordle’ To Life Via New Board Game

Starbox Bags $2.8M Contract In Malaysia For Licensing Its Software

Goldman Sachs Maintains Neutral on Equity Residential, Lowers Price Target to $74

Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus